Navigation Links
Patient Enrollment Complete in First Trial to Compare Physiologic Guidance vs. Angiographic Guidance of Stent Deployment in Patients with Multivessel Disease
Date:10/22/2007

WASHINGTON, Oct. 22 /PRNewswire/ -- Patient enrollment is complete in the first randomized, prospective, multicenter trial that will compare the clinical outcomes and cost-effectiveness of a physiologic-guided percutaneous coronary intervention (PCI) strategy to an angiographic-guided one in patients with multivessel coronary artery disease (CAD). Bernard De Bruyne, M.D., Ph.D., presented the study update today at the Transcatheter Cardiovascular Therapeutics symposium (TCT 2007) in Washington.

One thousand patients at 20 centers worldwide are participating in the FAME (Fractional flow reserve vs. Angiography for Multivessel Evaluation) study. Participants enrolled in the study meet the following criteria:

-- Coronary lesions in at least two of the three major cardiac vessels

have narrowings of greater than or equal to 50 percent by visual

assessment.

-- The lesions require stenting, according to the investigator.

-- The vessels are large enough to accommodate drug-eluting stents.

After an investigator's visual assessment of an angiogram and notation of which lesions appear to require stenting, patients will be assigned randomly to one of the two PCI strategies. Patients assigned to angiographic guidance will undergo stenting as planned, while patients assigned to physiologic guidance will have fractional flow reserve (FFR) measured in diseased vessels with a coronary pressure wire using a system provided by Radi Medical Systems AB. If FFR is less than or equal to 0.80, meaning the coronary pressure or flow beyond the narrowing is less than or equal to 80% of what it should be, the lesion will be stented.

The study's primary endpoint is a composite of major adverse cardiac events (MACE), including death, myocardial infarction and repeat coronary revascularization at one year. Secondary endpoints include global cost effectiveness after one year, cardiac death and myocardial infarction rate at one year, functional class at one year, number of anti-anginal drugs after one year, overall MACE rate at one month post-procedure and at six months, two, three and five years.

"With drug-eluting stents (DES) and lower restenosis rates, interventional cardiologists are performing PCI more often in patients with increasingly complex CAD, including multivessel disease," said Dr. De Bruyne. "Furthermore, some physicians are stenting all intermediate lesions with DES regardless of the physiologic significance of those lesions. DES are expensive and have been associated with potential late complications. Therefore, the objective of FAME is to help us identify an approach to PCI that will improve overall clinical outcomes and reduce healthcare expenditure."

In addition to Dr. De Bruyne, the FAME study's investigators are represented by Nico H. J. Pijls, M.D., Ph.D.; Pim Tonino, M.D.; Uwe Siebert, M.D., M.Sc., M.P.H., Sc.D.; and William Fearon, M.D. A paper outlining the rationale and design of the trial is published in the October issue of American Heart Journal (American Heart Journal Vol.154, No. 4, pp.632-636). For more information about the FAME study, visit http://clinicaltrials.gov/ct/gui/show/NCT00267774?order=17 .

Media Contacts:

David Schull or Benjamin Carmichael

Russo Partners

+1 212-845-4271

+1 858-717-2310 (during TCT 2007)

david.schull@russopartnersllc.com

benjamin.carmichael@russopartnersllc.com


'/>"/>
SOURCE Radi Medical Systems AB
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Monitoring Patient Glucose Levels: New Advances in software make it easier
2. Managing Preanalytical Processes for Patient Safety
3. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
4. Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing
5. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , Tenn. and DALLAS , April 19, ... Inc., announced that the first patients in ... EndoStim device in the Lower Esophageal Sphincter Stimulation for ... minimally-invasive implantable device designed to provide long-term reflux control ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... 19, 2017 Companion ... response in pets such as canine, avian and ... various types such as Attenuated Live Vaccines, Conjugate ... Vaccines and Recombinant Vaccines. Attenuated live vaccines are ... bacteria, which have been weakend under laboratory conditions. ...
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group leased ... is developing at Conejo Spectrum Business Park in ... Atara Biotherapeutics, Inc. , a biopharmaceutical company ... life-threatening diseases that have been underserved by scientific ... therapies for cancer, autoimmune and infectious disease. ...
Breaking Medicine Technology:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... expanded distribution of the GlycoMark test throughout the Northeast U.S. , GlycoMark ... patients with diabetes. The GlycoMark test provides a clinically proven one- to two-week ...
(Date:4/28/2017)... ... 2017 , ... Children and adolescents who enter the foster ... in the general population. That’s because foster care is designed to protect children ... no fault of their own, youth who have experienced trauma often have difficulty ...
(Date:4/28/2017)... ... April 28, 2017 , ... Bill Howe started his sewer and drain company ... Tina Howe joined the team, the Bill Howe brand was born and they began ... and giving back to the San Diego community in which they worked, lived and ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation ... supplements, through its Nova Skin Sciences division, recently announced the launch of Allumière ... with the power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... respiratory hospital, based in Denver, Colorado, announced an agreement to create the Jane ... continuing support of the Jane and Leonard Korman Family Foundation. The collaboration leverages ...
Breaking Medicine News(10 mins):